Show simple item record

Assessing the knowledge, perceptions, and practices of primary care clinicians toward pharmacogenetics

dc.contributor.authorJohengen, Emily K.
dc.contributor.authorWard, Kristen M.
dc.contributor.authorCoe, Antoinette B.
dc.contributor.authorPasternak, Amy L.
dc.date.accessioned2021-02-04T21:48:50Z
dc.date.available2022-02-04 16:48:49en
dc.date.available2021-02-04T21:48:50Z
dc.date.issued2021-01
dc.identifier.citationJohengen, Emily K.; Ward, Kristen M.; Coe, Antoinette B.; Pasternak, Amy L. (2021). "Assessing the knowledge, perceptions, and practices of primary care clinicians toward pharmacogenetics." Journal of the American College of Clinical Pharmacy 4(1): 27-32.
dc.identifier.issn2574-9870
dc.identifier.issn2574-9870
dc.identifier.urihttps://hdl.handle.net/2027.42/166164
dc.description.abstractIntroductionPharmacogenetics (PGx) testing is becoming increasingly available to patients and clinicians, but investigations of PGx testing in primary care and the pharmacist’s role in educating clinicians have been limited.ObjectivesThe objectives of this study were to: (a) determine the utilization of PGx testing in primary care clinics, (b) identify how clinicians document and act on PGx test results, and (c) determine clinician interest in PGx education or consultation from pharmacists.MethodsA 16‐item survey was distributed via email. Eligible participants included physicians, physician assistants, nurse practitioners, and pharmacists who work in family medicine, general medicine, geriatric, or pediatric primary care clinics at one academic medical center. Descriptive statistics were used to characterize the frequency of PGx tests ordered in primary care clinics, provider comfort with PGx test interpretation, documentation practices, and interest in PGx education or consultation from pharmacists.ResultsThe overall survey response rate was 15.8% (n = 55). Most respondents were physicians (84%). Nearly 40% of respondents reported having a patient bring PGx test results to a visit, while only 9% reported ordering a PGx test. Documentation practices were variable, and response to PGx results was most commonly no change in therapy (52%). Only two (3.6%) respondents agreed with the statement, “I feel confident in my ability to interpret PGx test results,” and the majority reported interest in PGx education. Eighty percent of respondents reported they would be likely or very likely to consult a PGx‐trained pharmacist for help interpreting PGx results.DiscussionClinicians in this survey were more likely to have patients bring in results than to order PGx tests, did not feel confident in result interpretation, and expressed interest in working with pharmacists for PGx test interpretation. This research can help guide the development of PGx‐focused pharmacy services and education for clinicians who are encountering PGx testing in their practice.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherprecision medicine
dc.subject.otherprimary health care
dc.subject.otherpharmacogenetics
dc.subject.otherpharmacists
dc.titleAssessing the knowledge, perceptions, and practices of primary care clinicians toward pharmacogenetics
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166164/1/jac51341.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166164/2/jac51341_am.pdf
dc.identifier.doi10.1002/jac5.1341
dc.identifier.doihttps://dx.doi.org/10.7302/87
dc.identifier.sourceJournal of the American College of Clinical Pharmacy
dc.identifier.citedreferenceKisor DF, Farrell CL. Expanding pharmacist and student pharmacist access to genetics/genomics/pharmacogenomics competency education. J Med Educ Curric Dev. 2019; 6: 1 – 10.
dc.identifier.citedreferenceLemke AA, Hutten Selkirk CG, Glaser NS, et al. Primary care physician experiences with integrated pharmacogenomics testing in a community health system. Pers Med. 2017; 14 ( 5 ): 389 – 400.
dc.identifier.citedreferenceFrigon MP, Blackburn ME, Dubois‐Bouchard C, Gagnon AL, Tardif S, Tremblay K. Pharmacogenetic testing in primary care practice: Opinions of physicians, pharmacists and patients. Pharmacogenomics. 2019; 20 ( 8 ): 589 – 598.
dc.identifier.citedreferenceMyers M. Health care providers and direct‐to‐consumer access and advertising of genetic testing in the United States. Genome Med. 2011; 3: 81.
dc.identifier.citedreferenceMcKillip RP, Borden BA, Galecki P, et al. Patient perceptions of care as influenced by a large institutional pharmacogenomic implementation program. Clin Pharmacol Ther. 2017; 102 ( 1 ): 106 – 114.
dc.identifier.citedreferenceCarere DA, VanderWeele TJ, Vassy JL, et al. Prescription medication changes following direct‐to‐consumer personal genomic testing: Findings from the Impact of Personal Genomics (PGen) Study. Genet Med. 2017; 19 ( 5 ): 537 – 545.
dc.identifier.citedreferenceCarroll JC, Allanson J, Morrison S, Miller FA, Wilson BJ, Permaul JA and Telner D. Informing Integration of Genomic Medicine Into Primary Care: An Assessment of Current Practice, Attitudes, and Desired Resources. Front. Genet. 2019; 10:1189. https://doi.org/10.3389/fgene.2019.01189
dc.identifier.citedreferenceU.S. Food and Drug Administration. FDA authorizes first direct‐to‐consumer test for detecting genetic variants that may be associated with medication metabolism [accessed 2020 August 3]. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-direct-consumer-test-detecting-genetic-variants-may-be-associated-medication.
dc.identifier.citedreferenceBloss CS, Schork NJ, Topol EJ. Direct‐to‐consumer pharmacogenomic testing is associated with increased physician utilization. J Med Genet. 2014; 51: 83 – 89.
dc.identifier.citedreferenceJust KS, Steffens M, Swen JJ, Patrinos GP, Guchelaar HJ, Stingl JC. Medical education in pharmacogenomics – Results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U‐PGx). Eur J Clin Pharmacol. 2017; 73: 1247 – 1252.
dc.identifier.citedreferenceRahawi S, Naik H, Blake KV, et al. Knowledge and attitudes on pharmacogenetics among pediatricians. J Hum Genet. 2020; 65: 437 – 444.
dc.identifier.citedreferenceClinical Pharmacogenetics Implementation Consortium. [accessed 2020 August 3]. Available from: https://cpicpgx.org.
dc.identifier.citedreferencePharmGKB. [accessed 2020 August 3]. Available from: https://www.pharmgkb.org.
dc.identifier.citedreferenceMarcinak R, Paris M, Kinney SRM. Pharmacogenomics education improves pharmacy student perceptions of their abilities and roles in its use. Am J Pharm Educ. 2018; 82 ( 9 ): 6424.
dc.identifier.citedreferenceLuzum JA, Luzum MJ. Physicians’ attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Pers Med. 2016; 13 ( 2 ): 119 – 127.
dc.identifier.citedreferenceCicali EJ, Weitzel KW, Elsey AR, et al. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings. Genet Med. 2019; 21 ( 10 ): 2264 – 2274.
dc.identifier.citedreferenceWeitzel KW, Duong BQ, Arwood MJ, et al. A stepwise approach to implementing pharmacogenetic testing in the primary care setting. Pharmacogenomics. 2019; 20 ( 15 ): 1103 – 1112.
dc.identifier.citedreferenceHaga SB, Mills R, Moaddeb J, Allen LaPointe N, Cho A, Ginsburg GS. Primary care providers’ use of pharmacist support for delivery of pharmacogenetic testing. Pharmacogenomics. 2017; 18 ( 4 ): 359 – 367.
dc.identifier.citedreferenceDressler LG, Bell GC, Abernathy PM, et al. Implementing pharmacogenetic testing in rural primary care practices: A pilot feasibility study. Pharmacogenomics. 2019; 20 ( 6 ): 443 – 446.
dc.identifier.citedreferenceGammal RS, Mayes J, Caudle KE. Ready or not, here it comes: Direct‐to‐consumer pharmacogenomic testing and its implications for community pharmacists. JAPhA. 2019; 59 ( 5 ): 646 – 650.
dc.identifier.citedreferenceDunnenberger HM, Biszewski M, Bell GC, et al. Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am J Health‐Syst Pharm. 2016; 73: 1956 – 1966.
dc.identifier.citedreferenceHicks JK, Dunnenberger HM, Gumpper KF, et al. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016; 73 ( 23 ): 1967 – 1976.
dc.identifier.citedreferenceCarabello PJ, Bielinski SJ, St. Sauver JL, et al. Electronic medical record‐integrated pharmacogenomics and related clinical decision support concepts. Clin Pharm Ther. 2017; 102 ( 2 ): 254 – 264.
dc.identifier.citedreferenceHaga SB, Kantor A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff (Millwood). 2018; 37 ( 5 ): 717 – 723.
dc.identifier.citedreferenceRigter T, Jansen ME, Groot JMd, Janssen SWJ, Rodenburg W and Cornel MC. Implementation of Pharmacogenetics in Primary Care: A Multi‐Stakeholder Perspective. Front. Genet. 2020; 11: 10. https://doi.org/10.3389/fgene.2020.00010
dc.identifier.citedreferenceU.S. Food and Drug Administration. Table of Pharmacogenetic Associations [accessed 2020 September 10]. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations.
dc.identifier.citedreferenceClinical Pharmacogenetics Implementation Consortium. CPIC® Guideline for NSAIDs based on CYP2C9 genotype [accessed 2020 September 10]. Available from: https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/.
dc.identifier.citedreferenceClinical Pharmacogenetics Implementation Consortium. CPIC® Guideline for Proton Pump Inhibitors and CYP2C19 [accessed 2020 September 10]. Available from: https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/.
dc.identifier.citedreferenceSwen JJ, Guchelaar HJ. Just how feasible is pharmacogenetic testing in the primary healthcare setting? Pharmacogenomics. 2012; 13 ( 5 ): 507 – 509.
dc.identifier.citedreferenceHaga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012; 82 ( 4 ): 388 – 394.
dc.identifier.citedreferenceStanek EJ, Sanders CL, Johansen Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: Results of a nationwide survey. Clin Pharm Ther. 2012; 91 ( 3 ): 450 – 458.
dc.working.doi10.7302/87en
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.